Risk of COVID-19 Diagnosis and Hospitalization in Patients with Osteoarthritis or Back Pain Treated with Ibuprofen Compared to Other NSAIDs or Paracetamol: A Network Cohort Study

{ 'indexed': {'date-parts': [[2023, 9, 20]], 'date-time': '2023-09-20T16:19:00Z', 'timestamp': 1695226740625}, 'reference-count': 28, 'publisher': 'Springer Science and Business Media LLC', 'issue': '3', 'license': [ { 'start': { 'date-parts': [[2023, 1, 24]], 'date-time': '2023-01-24T00:00:00Z', 'timestamp': 1674518400000}, 'content-version': 'tdm', 'delay-in-days': 0, 'URL': 'https://creativecommons.org/licenses/by-nc/4.0'}, { 'start': { 'date-parts': [[2023, 1, 24]], 'date-time': '2023-01-24T00:00:00Z', 'timestamp': 1674518400000}, 'content-version': 'vor', 'delay-in-days': 0, 'URL': 'https://creativecommons.org/licenses/by-nc/4.0'}], 'funder': [ { 'DOI': '10.13039/501100000272', 'name': 'National Institute for Health and Care Research', 'doi-asserted-by': 'publisher'}, {'name': 'Oxford Clarendon Foundation'}, {'name': 'Abbott contracted IQVIA for the conducting of this study'}, {'name': 'Had a contract with Abbott International, as Consultant for scientific projects'}], 'content-domain': {'domain': ['link.springer.com'], 'crossmark-restriction': False}, 'published-print': {'date-parts': [[2023, 2]]}, 'DOI': '10.1007/s40265-022-01822-z', 'type': 'journal-article', 'created': {'date-parts': [[2023, 1, 24]], 'date-time': '2023-01-24T12:34:35Z', 'timestamp': 1674563675000}, 'page': '249-263', 'update-policy': 'http://dx.doi.org/10.1007/springer_crossmark_policy', 'source': 'Crossref', 'is-referenced-by-count': 4, 'title': 'Risk of COVID-19 Diagnosis and Hospitalisation in Patients with Osteoarthritis or Back Pain ' 'Treated with Ibuprofen Compared to Other NSAIDs or Paracetamol: A Network Cohort Study', 'prefix': '10.1007', 'volume': '83', 'author': [ { 'ORCID': 'http://orcid.org/0000-0002-0040-0042', 'authenticated-orcid': False, 'given': 'Junqing', 'family': 'Xie', 'sequence': 'first', 'affiliation': []}, {'given': 'James T.', 'family': 'Brash', 'sequence': 'additional', 'affiliation': []}, {'given': 'Cigdem', 'family': 'Turkmen', 'sequence': 'additional', 'affiliation': []}, {'given': 'Stefan', 'family': 'Driessen', 'sequence': 'additional', 'affiliation': []}, {'given': 'Giustino', 'family': 'Varrassi', 'sequence': 'additional', 'affiliation': []}, {'given': 'George', 'family': 'Argyriou', 'sequence': 'additional', 'affiliation': []}, {'given': 'Sarah', 'family': 'Seager', 'sequence': 'additional', 'affiliation': []}, {'given': 'Christian', 'family': 'Reich', 'sequence': 'additional', 'affiliation': []}, { 'ORCID': 'http://orcid.org/0000-0002-3950-6346', 'authenticated-orcid': False, 'given': 'Daniel', 'family': 'Prieto-Alhambra', 'sequence': 'additional', 'affiliation': []}], 'member': '297', 'published-online': {'date-parts': [[2023, 1, 24]]}, 'reference': [ { 'key': '1822_CR1', 'doi-asserted-by': 'publisher', 'DOI': '10.1136/bmj.m1086', 'volume': '368', 'author': 'M Day', 'year': '2020', 'unstructured': 'Day M. Covid-19: ibuprofen should not be used for managing symptoms, say ' 'doctors and scientists. BMJ. 2020;368: m1086. ' 'https://doi.org/10.1136/bmj.m1086.', 'journal-title': 'BMJ'}, { 'key': '1822_CR2', 'doi-asserted-by': 'publisher', 'DOI': '10.1136/bmj.m1555', 'volume': '369', 'author': 'I Torjesen', 'year': '2020', 'unstructured': 'Torjesen I. Covid-19: ibuprofen can be used for symptoms, says UK ' 'agency, but reasons for change in advice are unclear. BMJ. 2020;369: ' 'm1555. https://doi.org/10.1136/bmj.m1555.', 'journal-title': 'BMJ'}, { 'key': '1822_CR3', 'unstructured': 'Roy S. Coronavirus: alerte sur l’ibuprofène et autres ' 'anti-inflammatoires. Le Figaro. Updated March 14, 2020. 2022. ' 'https://www.lefigaro.fr/sciences/coronavirus-alerte-sur-l-ibuprofene-et-autres-anti-inflammatoires-20200314. ' 'Accessed 28 Feb 2022.'}, { 'key': '1822_CR4', 'doi-asserted-by': 'publisher', 'unstructured': 'Fernandez-Gutierrez B, Leon L, Madrid A, et al. Hospital admissions in ' 'inflammatory rheumatic diseases during the peak of COVID-19 pandemic: ' 'incidence and role of disease-modifying agents. Ther Adv Musculoskelet ' 'Dis. 2021. doi: https://doi.org/10.1177/1759720X20962692.', 'DOI': '10.1177/1759720X20962692'}, { 'issue': '4', 'key': '1822_CR5', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/S2213-2600(20)30116-8', 'volume': '8', 'author': 'L Fang', 'year': '2020', 'unstructured': 'Fang L, Karakiulakis G, Roth M. Are patients with hypertension and ' 'diabetes mellitus at increased risk for COVID-19 infection? Lancet ' 'Respir Med. 2020;8(4): e21. ' 'https://doi.org/10.1016/S2213-2600(20)30116-8.', 'journal-title': 'Lancet Respir Med'}, { 'issue': '2', 'key': '1822_CR6', 'doi-asserted-by': 'publisher', 'first-page': '271', 'DOI': '10.1016/j.cell.2020.02.052', 'volume': '181', 'author': 'M Hoffmann', 'year': '2020', 'unstructured': 'Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 cell entry ' 'depends on ACE2 and TMPRSS2 and is blocked by a clinically proven ' 'protease inhibitor. Cell. 2020;181(2):271-80.e8. ' 'https://doi.org/10.1016/j.cell.2020.02.052.', 'journal-title': 'Cell'}, { 'issue': '5', 'key': '1822_CR7', 'doi-asserted-by': 'publisher', 'first-page': '785', 'DOI': '10.1136/ard.2010.128637', 'volume': '70', 'author': 'K Au', 'year': '2011', 'unstructured': 'Au K, Reed G, Curtis JR, et al. High disease activity is associated with ' 'an increased risk of infection in patients with rheumatoid arthritis. ' 'Ann Rheum Dis. 2011;70(5):785–91. ' 'https://doi.org/10.1136/ard.2010.128637.', 'journal-title': 'Ann Rheum Dis'}, { 'key': '1822_CR8', 'unstructured': 'European Medicines Agency. EMA gives advice on the use of non-steroidal ' 'anti-inflammatories for COVID-19. 2020. ' 'https://www.ema.europa.eu/en/news/ema-gives-advice-use-non-steroidal-anti-inflammatories-covid-19. ' 'Accessed 5 Jul 2020 .'}, { 'key': '1822_CR9', 'doi-asserted-by': 'publisher', 'unstructured': 'Monti S, Montecucco C. Non-steroidal anti-inflammatory treatment during ' "COVID-19: friend or foe? Response to: 'Coronavirus disease 19 (Covid-19) " "and non-steroidal anti-inflammatory drugs (NSAID)' by Giollo et al. Ann " 'Rheum Dis. ' '2021;80(2):e13.https://doi.org/10.1136/annrheumdis-2020-217638', 'DOI': '10.1136/annrheumdis-2020-217638'}, { 'key': '1822_CR10', 'unstructured': 'NICE. Key messages. COVID-19 rapid evidence summary: acute use of ' 'non-steroidal anti-inflammatory drugs (NSAIDs) for people with or at ' 'risk of COVID-19. 2020. ' 'https://www.nice.org.uk/advice/es23/chapter/Key-messages. Accessed 5 ' 'July 2020.'}, { 'issue': '5', 'key': '1822_CR11', 'doi-asserted-by': 'publisher', 'first-page': '731', 'DOI': '10.1002/art.41593', 'volume': '73', 'author': 'JS Chandan', 'year': '2021', 'unstructured': 'Chandan JS, Zemedikun DT, Thayakaran R, et al. Nonsteroidal ' 'antiinflammatory drugs and susceptibility to COVID-19. Arthritis ' 'Rheumatol. 2021;73(5):731–9. https://doi.org/10.1002/art.41593.', 'journal-title': 'Arthritis Rheumatol'}, { 'issue': '7', 'key': '1822_CR12', 'doi-asserted-by': 'publisher', 'first-page': '943', 'DOI': '10.1136/annrheumdis-2020-219517', 'volume': '80', 'author': 'AY Wong', 'year': '2021', 'unstructured': 'Wong AY, MacKenna B, Morton CE, et al. Use of non-steroidal ' 'anti-inflammatory drugs and risk of death from COVID-19: an OpenSAFELY ' 'cohort analysis based on two cohorts. Ann Rheum Dis. 2021;80(7):943–51. ' 'https://doi.org/10.1136/annrheumdis-2020-219517.', 'journal-title': 'Ann Rheum Dis'}, { 'key': '1822_CR13', 'unstructured': 'OHDSI. OMOP Common Data Model. 2021. ' 'https://www.ohdsi.org/data-standardization/the-common-data-model/. ' 'Accessed 7 Oct 2021.'}, { 'key': '1822_CR14', 'doi-asserted-by': 'publisher', 'first-page': '369', 'DOI': '10.2147/CLEP.S323292', 'volume': '14', 'author': 'D Prieto-Alhambra', 'year': '2022', 'unstructured': 'Prieto-Alhambra D, Kostka K, Duarte-Salles T, et al. Unraveling ' 'COVID-19: a large-scale characterization of 4.5 million COVID-19 cases ' 'using CHARYBDIS. Clin Epidemiol. 2022;14:369–84. ' 'https://doi.org/10.2147/CLEP.S323292.', 'journal-title': 'Clin Epidemiol.'}, { 'key': '1822_CR15', 'doi-asserted-by': 'publisher', 'DOI': '10.1136/bmj.n1038', 'volume': '373', 'author': 'A Prats-Uribe', 'year': '2021', 'unstructured': 'Prats-Uribe A, Sena AG, Lai LYH, et al. Use of repurposed and adjuvant ' 'drugs in hospital patients with COVID-19: multinational network cohort ' 'study. BMJ. 2021;373: n1038. https://doi.org/10.1136/bmj.n1038.', 'journal-title': 'BMJ'}, { 'issue': '2', 'key': '1822_CR16', 'doi-asserted-by': 'publisher', 'first-page': '185', 'DOI': '10.2307/2348252', 'volume': '41', 'author': 'M Woodward', 'year': '1992', 'unstructured': 'Woodward M. Formulae for sample size, power and minimum detectable ' 'relative risk in medical studies. J R Stat Soc D. 1992;41(2):185. ' 'https://doi.org/10.2307/2348252.', 'journal-title': 'J R Stat Soc D.'}, { 'issue': '6', 'key': '1822_CR17', 'doi-asserted-by': 'publisher', 'first-page': '2005', 'DOI': '10.1093/ije/dyy120', 'volume': '47', 'author': 'Y Tian', 'year': '2018', 'unstructured': 'Tian Y, Schuemie MJ, Suchard MA. Evaluating large-scale propensity score ' 'performance through real-world and synthetic data experiments. Int J ' 'Epidemiol. 2018;47(6):2005–14. https://doi.org/10.1093/ije/dyy120.', 'journal-title': 'Int J Epidemiol'}, { 'issue': '22', 'key': '1822_CR18', 'doi-asserted-by': 'publisher', 'first-page': '3883', 'DOI': '10.1002/sim.6977', 'volume': '35', 'author': 'MJ Schuemie', 'year': '2016', 'unstructured': 'Schuemie MJ, Hripcsak G, Ryan PB, Madigan D, Suchard MA. Robust ' 'empirical calibration of p-values using observational data. Stat Med. ' '2016;35(22):3883–8. https://doi.org/10.1002/sim.6977.', 'journal-title': 'Stat Med'}, { 'issue': '11', 'key': '1822_CR19', 'doi-asserted-by': 'publisher', 'first-page': '2571', 'DOI': '10.1073/pnas.1708282114', 'volume': '115', 'author': 'MJ Schuemie', 'year': '2018', 'unstructured': 'Schuemie MJ, Hripcsak G, Ryan PB, Madigan D, Suchard MA. Empirical ' 'confidence interval calibration for population-level effect estimation ' 'studies in observational healthcare data. Proc Natl Acad Sci USA. ' '2018;115(11):2571–7. https://doi.org/10.1073/pnas.1708282114.', 'journal-title': 'Proc Natl Acad Sci USA'}, { 'issue': '1', 'key': '1822_CR20', 'doi-asserted-by': 'publisher', 'first-page': '31', 'DOI': '10.1177/0962280210386207', 'volume': '21', 'author': 'ML Petersen', 'year': '2012', 'unstructured': 'Petersen ML, Porter KE, Gruber S, Wang Y, van der Laan MJ. Diagnosing ' 'and responding to violations in the positivity assumption. Stat Methods ' 'Med Res. 2012;21(1):31–54. https://doi.org/10.1177/0962280210386207.', 'journal-title': 'Stat Methods Med Res'}, { 'issue': '7503', 'key': '1822_CR21', 'doi-asserted-by': 'publisher', 'first-page': '92', 'DOI': '10.1038/nature13479', 'volume': '510', 'author': 'CN Serhan', 'year': '2014', 'unstructured': 'Serhan CN. Pro-resolving lipid mediators are leads for resolution ' 'physiology. Nature. 2014;510(7503):92–101. ' 'https://doi.org/10.1038/nature13479.', 'journal-title': 'Nature'}, { 'issue': '7', 'key': '1822_CR22', 'doi-asserted-by': 'publisher', 'first-page': '612', 'DOI': '10.1038/89759', 'volume': '2', 'author': 'BD Levy', 'year': '2001', 'unstructured': 'Levy BD, Clish CB, Schmidt B, Gronert K, Serhan CN. Lipid mediator class ' 'switching during acute inflammation: signals in resolution. Nat Immunol. ' '2001;2(7):612–9. https://doi.org/10.1038/89759.', 'journal-title': 'Nat Immunol'}, { 'issue': '2', 'key': '1822_CR23', 'doi-asserted-by': 'publisher', 'first-page': '97', 'DOI': '10.1159/000375362', 'volume': '131', 'author': 'W Qiao', 'year': '2015', 'unstructured': 'Qiao W, Wang C, Chen B, et al. Ibuprofen attenuates cardiac fibrosis in ' 'streptozotocin-induced diabetic rats. Cardiology. 2015;131(2):97–106. ' 'https://doi.org/10.1159/000375362.', 'journal-title': 'Cardiology'}, { 'issue': '1', 'key': '1822_CR24', 'doi-asserted-by': 'publisher', 'first-page': '253', 'DOI': '10.1007/s40121-020-00363-w', 'volume': '10', 'author': 'LC Abu Esba', 'year': '2021', 'unstructured': 'Abu Esba LC, Alqahtani RA, Thomas A, Shamas N, Alswaidan L, Mardawi G. ' 'Ibuprofen and NSAID use in COVID-19 infected patients is not associated ' 'with worse outcomes: a prospective cohort study. Infect Dis Ther. ' '2021;10(1):253–68. https://doi.org/10.1007/s40121-020-00363-w.', 'journal-title': 'Infect Dis Ther'}, { 'key': '1822_CR25', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/S2665-9913(21)00104-1', 'author': 'TM Drake', 'year': '2021', 'unstructured': 'Drake TM, Fairfield CJ, Pius R, et al. Non-steroidal anti-inflammatory ' 'drug use and outcomes of COVID-19 in the ISARIC Clinical ' 'Characterisation Protocol UK cohort: a matched, prospective cohort ' 'study. Lancet Rheumatol. 2021. ' 'https://doi.org/10.1016/S2665-9913(21)00104-1.', 'journal-title': 'Lancet Rheumatol'}, { 'issue': '3', 'key': '1822_CR26', 'doi-asserted-by': 'publisher', 'first-page': '641', 'DOI': '10.1007/s10787-021-00810-1', 'volume': '29', 'author': 'CS Kow', 'year': '2021', 'unstructured': 'Kow CS, Hasan SS. The risk of mortality in patients with COVID-19 with ' 'pre-diagnosis use of NSAIDs: a meta-analysis. Inflammopharmacology. ' '2021;29(3):641–4. https://doi.org/10.1007/s10787-021-00810-1.', 'journal-title': 'Inflammopharmacology'}, { 'issue': '1', 'key': '1822_CR27', 'doi-asserted-by': 'publisher', 'first-page': '5087', 'DOI': '10.1038/s41598-021-84539-5', 'volume': '11', 'author': 'J Park', 'year': '2021', 'unstructured': 'Park J, Lee S-H, You SC, Kim J, Yang K. Non-steroidal anti-inflammatory ' 'agent use may not be associated with mortality of coronavirus disease ' '19. Sci Rep. 2021;11(1):5087. ' 'https://doi.org/10.1038/s41598-021-84539-5.', 'journal-title': 'Sci Rep'}, { 'key': '1822_CR28', 'doi-asserted-by': 'publisher', 'first-page': '1061', 'DOI': '10.2147/TCRM.S79135', 'volume': '11', 'author': 'N Moore', 'year': '2015', 'unstructured': 'Moore N, Pollack C, Butkerait P. Adverse drug reactions and drug-drug ' 'interactions with over-the-counter NSAIDs. Ther Clin Risk Manag. ' '2015;11:1061–75. https://doi.org/10.2147/TCRM.S79135.', 'journal-title': 'Ther Clin Risk Manag'}], 'container-title': 'Drugs', 'original-title': [], 'language': 'en', 'link': [ { 'URL': 'https://link.springer.com/content/pdf/10.1007/s40265-022-01822-z.pdf', 'content-type': 'application/pdf', 'content-version': 'vor', 'intended-application': 'text-mining'}, { 'URL': 'https://link.springer.com/article/10.1007/s40265-022-01822-z/fulltext.html', 'content-type': 'text/html', 'content-version': 'vor', 'intended-application': 'text-mining'}, { 'URL': 'https://link.springer.com/content/pdf/10.1007/s40265-022-01822-z.pdf', 'content-type': 'application/pdf', 'content-version': 'vor', 'intended-application': 'similarity-checking'}], 'deposited': { 'date-parts': [[2023, 2, 15]], 'date-time': '2023-02-15T07:30:28Z', 'timestamp': 1676446228000}, 'score': 1, 'resource': {'primary': {'URL': 'https://link.springer.com/10.1007/s40265-022-01822-z'}}, 'subtitle': [], 'short-title': [], 'issued': {'date-parts': [[2023, 1, 24]]}, 'references-count': 28, 'journal-issue': {'issue': '3', 'published-print': {'date-parts': [[2023, 2]]}}, 'alternative-id': ['1822'], 'URL': 'http://dx.doi.org/10.1007/s40265-022-01822-z', 'relation': {}, 'ISSN': ['0012-6667', '1179-1950'], 'subject': ['Pharmacology (medical)'], 'container-title-short': 'Drugs', 'published': {'date-parts': [[2023, 1, 24]]}, 'assertion': [ { 'value': '27 November 2022', 'order': 1, 'name': 'accepted', 'label': 'Accepted', 'group': {'name': 'ArticleHistory', 'label': 'Article History'}}, { 'value': '24 January 2023', 'order': 2, 'name': 'first_online', 'label': 'First Online', 'group': {'name': 'ArticleHistory', 'label': 'Article History'}}, {'order': 1, 'name': 'Ethics', 'group': {'name': 'EthicsHeading', 'label': 'Declarations'}}, { 'value': 'Abbott contracted IQVIA for the conduct of this study. Prof. Prieto-Alhambra ' 'receives funding from the UK National Institute for Health Research in the form ' 'of a Senior Research Fellowship, and as part of the Oxford National Institute ' 'for Health Research Biomedical Research Centre. Prof. Giustino Varrassi had a ' 'contract with Abbott International, as a consultant for scientific projects. He ' 'is also a consultant for scientific projects with Dompé Farmaceutici and ' 'Menarini Group.', 'order': 2, 'name': 'Ethics', 'group': {'name': 'EthicsHeading', 'label': 'Funding'}}, { 'value': 'All authors have completed the ICMJE disclosure form at ExternalRef removed and ' 'declare the following interests: Dani Prieto-Alhambra receives funding from the ' 'UK National Institute for Health Research in the form of a senior research ' 'fellowship and from the Oxford National Institute for Health Research ' 'Biomedical Research Centre. Junqing Xie receives the Clarendon Fund and Jardine ' 'scholarship (University of Oxford) to support her DPhil study. Dani ' 'Prieto-Alhambra’s research group has received research grants from the European ' 'Medicines Agency, the Innovative Medicines Initiative, Amgen, Chiesi and UCB ' 'Biopharma; and consultancy or speaker fees from Astellas, Amgen, AstraZeneca ' 'and UCB Biopharma.', 'order': 3, 'name': 'Ethics', 'group': {'name': 'EthicsHeading', 'label': 'Conflicts of Interest/Competing Interests'}}, { 'value': 'These assets are de-identified, commercially available data products that could ' 'be purchased and licensed by any researcher. The collection and ' 'de-identification of these data assets is a process that is commercial ' 'intellectual property and not privileged to the data licensees and the ' 'co-authors on this study. Licensees of these data have signed data use ' 'agreements with the data vendors that detail the usage protocols for running ' 'retrospective research on these databases. All analyses performed in this study ' 'were in accordance with data use agreement terms as specified by the data ' 'owners. As these data are deemed commercial assets, there is no institutional ' 'review board applicable to the usage and dissemination of these result sets or ' 'required registration of the protocol with additional ethics oversight. ' 'Compliance with data use agreement terms, which stipulate how these data can be ' 'used and for what purpose, is sufficient for the licensing commercial entities.', 'order': 4, 'name': 'Ethics', 'group': {'name': 'EthicsHeading', 'label': 'Ethics Approval'}}, { 'value': 'Not applicable.', 'order': 5, 'name': 'Ethics', 'group': {'name': 'EthicsHeading', 'label': 'Consent to Participate'}}, { 'value': 'Not applicable.', 'order': 6, 'name': 'Ethics', 'group': {'name': 'EthicsHeading', 'label': 'Consent for Publication'}}, { 'value': 'Patient-level data cannot be shared without approval from data custodians owing ' 'to local information governance and data protection regulations. Additional ' 'summary data, analytical code and detailed definitions of algorithms for ' 'identifying the events are available from the corresponding author on ' 'reasonable request to access the GitHub repository.', 'order': 7, 'name': 'Ethics', 'group': {'name': 'EthicsHeading', 'label': 'Availability of Data and Material'}}, { 'value': 'Not applicable.', 'order': 8, 'name': 'Ethics', 'group': {'name': 'EthicsHeading', 'label': 'Code Availability'}}, { 'value': 'JQ-X, DP-A, SS, CT and GV conceived the study and contributed to the study ' 'design. JQ-X, JB and JA conducted the statistical analyses. JQ-X and DP-A ' 'interpreted the results and wrote the manuscript. All authors contributed to ' 'writing the manuscript, approved the final version and had final responsibility ' 'for the decision to submit for publication. The lead authors (JQ-X and JB) ' 'affirm that this manuscript is an honest, accurate and transparent account of ' 'the study being reported, that no important aspects of the study have been ' 'omitted and that any discrepancies from the study as planned (and, if relevant, ' 'registered) have been explained. DP-A is the guarantor. The corresponding ' 'author attests that all listed authors meet authorship criteria and that no ' 'others meeting the criteria have been omitted.', 'order': 9, 'name': 'Ethics', 'group': {'name': 'EthicsHeading', 'label': 'Authors’ Contributors'}}]}